Panelists provide their perspective on the appropriate settings in which to use Zerbaxa (ceftolozane) or Avycaz (ceftazidime/avibactam) for Pseudomonas infections and reflect on which dosing methods are the safest.
Panelists discuss their personal approaches to treating Pseudomonas infections when an earlier strategy has failed, taking into consideration past treatments, a patient’s sepsis status, and timely decision making.
